Q-omics provides the consensus-scored ZSCAN10 profile across patient tissues and cancer cell-line models. ZSCAN10 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZSCAN10 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, ZSCAN10 RNA expression shows 13,168 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where ZSCAN10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN10 survival associations across molecular data types. ZSCAN10 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN10 RNA expression–survival associations across cancer types. High ZSCAN10 expression shows unfavorable associations in KIRC, ACC, KICH, MESO and THCA, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZSCAN10 RNA expression.
This table summarizes ZSCAN10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZSCAN10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN10 shows higher tumor expression in HNSC, LIHC, KIRP, STAD, CHOL and KIRC. The HNSC box plot shows higher ZSCAN10 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p < 0.001).
This table shows molecular features associated with ZSCAN10 in patient tissues and cancer cell lines. In patient samples, ZSCAN10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
